<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01891552</url>
  </required_header>
  <id_info>
    <org_study_id>TACETUX01</org_study_id>
    <nct_id>NCT01891552</nct_id>
  </id_info>
  <brief_title>Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab</brief_title>
  <acronym>TACETUX</acronym>
  <official_title>Observational Study on Second Line Treatment of Colorectal Liver Metastases (KRas wt) by Hepatic Intra-arterial Chemoembolization With Dc Beads 70-150 μm Microspheres Preloaded With Irinotecan 200 Mgr Plus Systemic Cetuximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Group of Endovascular Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Group of Endovascular Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The recently introduced chemoembolization has been considered to be a very attractive&#xD;
           new method in terms of response in the treatment of liver metastases from colon cancer&#xD;
           carcinoma (LM-CRC). It appears to be particularly useful if carried out with the new&#xD;
           embolization materials.&#xD;
&#xD;
        -  An 80% response rate was reported using TACE with Irinotecan pre-loaded Beads in&#xD;
           patients with liver metastases from colon cancer, who had been pretreated with 2 or more&#xD;
           lines of chemotherapy.&#xD;
&#xD;
        -  Since a greater activity was attained by a combination of Cetuximab and Irinotecan&#xD;
           versus Cetuximab in monotherapy, the European Agency for the Evaluation of Medicinal&#xD;
           Products (EMEA) has granted authorization to the use of Cetuximab in association with&#xD;
           irinotecan in the treatment of irinotecan-refractory CRC-LM.&#xD;
&#xD;
        -  In this study we want to collect data on on time to progression and tolerability using&#xD;
           DEBIRI+Cetuximab in LM-CRC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study and the treatment is related to the experiences and economical&#xD;
      availability of each center.&#xD;
&#xD;
      Primary objective: To collect data on time to progression (local and/or distant progression)&#xD;
      after administration of Dc-Beads microspheres preloaded with Irinotecan 200 mgr via hepatic&#xD;
      intra-arterial locoregional delivery (TACE) in/without association with standard weekly&#xD;
      therapy with Cetuximab.&#xD;
&#xD;
      Secondary objectives: To collect data on tolerability of treatment and improvement of quality&#xD;
      of life (Edmonton Symptom Assessment System (ESAS))&#xD;
&#xD;
      Treatment under observation :&#xD;
&#xD;
      Program A ( for all patients)&#xD;
&#xD;
      Day +1:&#xD;
&#xD;
      Lobar Infusion (lobe with dominant disease) of Irinotecan 100 mg preloaded into 2 ml of&#xD;
      70-150 µm M1 microspheres.&#xD;
&#xD;
      Second lobar infusion of Irinotecan 100 mg preloaded into 2 ml of 70-150 µm M1 microspheres&#xD;
      can be administered at the same time contralaterally or in a further TACE.&#xD;
&#xD;
      Day +30: The above procedure is repeated. Day +90: In case of response, a third&#xD;
      administration following the above procedures will be repeated&#xD;
&#xD;
      Program B ( for Centers in which Cetuximab is available) 5.2 Cetuximab administered as per&#xD;
      standard scheme: Day -15: loading dose with 400 mg/mq i.v. over a 2-hour period Day +21 and&#xD;
      subsequent weekly administrations: 250 mg/mq i.v. over a one hour period.&#xD;
&#xD;
      It is pointed out that administration of Cetuximab will be continued following the timeline&#xD;
      of the first infusion relative to the intra-arterial administration.&#xD;
&#xD;
      Evaluation of response&#xD;
&#xD;
      Response must be assessed by repeating the following examinations at Day 30, Day 90 and Day&#xD;
      120 after start of treatment:&#xD;
&#xD;
      Chest-abdomen CAT scan with and without contrast medium (refer to Section 4). Evaluation will&#xD;
      be based on the Response Evaluation Criteria In Solid Tumors (RECIST) cancer markers (CEA,&#xD;
      Carbohydrate Antigen (CA) 19.9)&#xD;
&#xD;
      Assessment of quality of life The Edmonton Symptom Assessment System (ESAS) is used to&#xD;
      monitor health conditions and quality of life.&#xD;
&#xD;
      The questionnaire must be filled in by the patient unaided by family members or by health&#xD;
      care personnel, over a period of about 15 minutes. Assessment of quality of life will be&#xD;
      performed during the baseline visit and at Day 30, Day 60 and Day 120 from start of&#xD;
      treatment.&#xD;
&#xD;
      It is important for the questionnaire to be completed by the patient before undergoing the&#xD;
      physical examination, in other words before discussing with the physician about any&#xD;
      examinations which might give an indication of the favorable or unfavorable course of the&#xD;
      disease. In providing the questionnaire to the patient, the physician will explain how to&#xD;
      complete it without discussing the contents of the questions, and once the patient has&#xD;
      completed the questionnaire, the physician will check that all questions have been answered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>time to progression</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>4 months</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Colon Cancer Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>Tacetux</arm_group_label>
    <description>DEBIRI+ CETUXIMAB ADMINISTRATION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEBIRI</arm_group_label>
    <description>only DEBIRI treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Unresectable hepatic metastases from colorectal carcinoma (CRC-LM)&#xD;
&#xD;
          2. Progression of disease after first line therapy containing Irinotecan completed at&#xD;
             least one month previously&#xD;
&#xD;
          3. Performance status (PS) 0-2&#xD;
&#xD;
          4. Biochemistry parameters within normal limits (ALT and gamma glutamyl transpeptidase&#xD;
             not exceeding three times the upper limit of normal, total bilirubin not exceeding 2.5&#xD;
             mg/ml)&#xD;
&#xD;
          5. Adequate information and subsequent written informed consent&#xD;
&#xD;
          6. Life expectancy &gt; 3 months&#xD;
&#xD;
          7. Patients K-RAS wild type&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Extension of disease greater than 50% of the parenchymal liver (confirmed by CAT scan&#xD;
             or MRI)&#xD;
&#xD;
          2. Brain metastases&#xD;
&#xD;
          3. Severe and confirmed vascular diseases&#xD;
&#xD;
          4. Other concomitant malignancies except for cutaneous basal cell carcinoma or carcinoma&#xD;
             in situ of the uterine cervix&#xD;
&#xD;
          5. Evidence of significant diseases such as uncontrolled diabetes, congestive heart&#xD;
             failure, chronic renal insufficiency (CRI)&#xD;
&#xD;
          6. Known hypersensitivity reactions towards components of the study drugs&#xD;
&#xD;
          7. Pregnant or breastfeeding women or women of childbearing potential not making use of&#xD;
             effective contraceptives&#xD;
&#xD;
          8. Family, psychological, social or geographical circumstances preventing the patient&#xD;
             from undergoing follow-up and from complying with protocol procedures&#xD;
&#xD;
          9. Patients K-RAS mutant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GIAMMARIA FIORENTINI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Group of Endovascular Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <state>PU</state>
        <zip>61122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://igevo.jimdo.com/</url>
    <description>International group of endovascular oncology (IGEVO) website</description>
  </link>
  <results_reference>
    <citation>Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V, Coschiera P. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012 Apr;32(4):1387-95. Erratum in: Anticancer Res. 2013 Nov;33(11):5211.</citation>
    <PMID>22493375</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2013</study_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>International Group of Endovascular Oncology</investigator_affiliation>
    <investigator_full_name>Giammaria Fiorentini</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Colon Cancer, Liver Metastasis, DEBIRI, cetuximab, efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

